EriosemationCAS# 162616-72-0 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 162616-72-0 | SDF | Download SDF |
PubChem ID | 15291690 | Appearance | Powder |
Formula | C19H22O4 | M.Wt | 314.4 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 5,7-dihydroxy-6,8-bis(3-methylbut-2-enyl)chromen-4-one | ||
SMILES | CC(=CCC1=C(C2=C(C(=C1O)CC=C(C)C)OC=CC2=O)O)C | ||
Standard InChIKey | DNZGQFQVMYCNOP-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H22O4/c1-11(2)5-7-13-17(21)14(8-6-12(3)4)19-16(18(13)22)15(20)9-10-23-19/h5-6,9-10,21-22H,7-8H2,1-4H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Eriosemation significant androgen receptor (AR) inhibition activity, suggests that it could be a promising candidate for further evaluation for prostate cancer prevention or management. |
Targets | Androgen Receptor |
Eriosemation Dilution Calculator
Eriosemation Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1807 mL | 15.9033 mL | 31.8066 mL | 63.6132 mL | 79.5165 mL |
5 mM | 0.6361 mL | 3.1807 mL | 6.3613 mL | 12.7226 mL | 15.9033 mL |
10 mM | 0.3181 mL | 1.5903 mL | 3.1807 mL | 6.3613 mL | 7.9517 mL |
50 mM | 0.0636 mL | 0.3181 mL | 0.6361 mL | 1.2723 mL | 1.5903 mL |
100 mM | 0.0318 mL | 0.159 mL | 0.3181 mL | 0.6361 mL | 0.7952 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Isolupalbigenin
Catalog No.:BCN6835
CAS No.:162616-70-8
- 3-Hydroxy-5,7-dimethoxy-3',4'-methylenedioxyflavan
Catalog No.:BCN1540
CAS No.:162602-04-2
- Broussoflavonol F
Catalog No.:BCN3571
CAS No.:162558-94-3
- Fmoc-Dap(Boc)-OH
Catalog No.:BCC3188
CAS No.:162558-25-0
- CDP 840 hydrochloride
Catalog No.:BCC7814
CAS No.:162542-90-7
- Salirasib
Catalog No.:BCC1918
CAS No.:162520-00-5
- Subelliptenone G
Catalog No.:BCN1720
CAS No.:162473-22-5
- VR23
Catalog No.:BCC6523
CAS No.:1624602-30-7
- Stilbostemin B
Catalog No.:BCN4697
CAS No.:162411-67-8
- GR 103691
Catalog No.:BCC6941
CAS No.:162408-66-4
- 3-Cyclopropylmethoxy-4-difluoromethoxybenzoic acid
Catalog No.:BCC8628
CAS No.:162401-62-9
- Roflumilast
Catalog No.:BCN2182
CAS No.:162401-32-3
- Sorokinianin
Catalog No.:BCN6978
CAS No.:162616-73-1
- Temsirolimus
Catalog No.:BCC3678
CAS No.:162635-04-3
- AZD3759
Catalog No.:BCC6475
CAS No.:1626387-80-1
- AT 56
Catalog No.:BCC6036
CAS No.:162640-98-4
- HQL 79
Catalog No.:BCC7703
CAS No.:162641-16-9
- 6-Deoxyjacareubin
Catalog No.:BCN6573
CAS No.:16265-56-8
- Kaempferol tetraacetate
Catalog No.:BCN1721
CAS No.:16274-11-6
- 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran
Catalog No.:BCN1539
CAS No.:16274-33-2
- 1-Hydroxy-2-prenylnaphthalene
Catalog No.:BCN1722
CAS No.:16274-34-3
- AZD8186
Catalog No.:BCC6470
CAS No.:1627494-13-6
- LDN-214117
Catalog No.:BCC5528
CAS No.:1627503-67-6
- Anemarrhena B
Catalog No.:BCN7592
CAS No.:1627521-95-2
Structure Based docking studies towards exploring potential anti-androgen activity of selected phytochemicals against Prostate Cancer.[Pubmed:28512306]
Sci Rep. 2017 May 16;7(1):1955.
Prostate cancer (PCa) is the second most common malignancy amongst men worldwide. Under PCa maintenance therapy drugs acting as antagonists/partial agonists of hormone receptors against the prostate tissue are used in clinical practices. Prominent drugs being Cyproterone acetate, Flutamide, Bicalutamide, they not only cause acute and long-term toxicity, but also develops drug resistance among patients. Our focus has been on phytochemicals which do not exhibit any cytotoxicity and have significant androgen receptor (AR) inhibition activity. As Protein- Ligand interactions play a key role in structure based drug design, so by using molecular docking, we screened 803 phytochemicals and investigated their binding affinity against AR. The three dimensional (3D) structure of AR was retrieved from Protein Data Bank, and docked with 3D Pubchem structures of 803 phytochemicals using Argus Lab. Molecular docking and drug likeness studies were made using ADMET properties while Lipinski's rule of five was performed for the phytochemicals to evaluate their anti-prostate cancer activity. The results showed that Isobavachin exhibited best binding affinity of -13.73 kcal/mol with AR followed by Glabranin, Anthocyanin and Eriosemation. Our studies therefore reveal that these four phytochemicals could be promising candidates for further evaluation for PCa prevention or management.